AIM: To evaluate central macular thickness(CMT) and mean choroidal thickness(MCT) in eyes with branch retinal vein occlusion(BRVO), before and after ranibizumab treatment using spectral domain-optical coherence tomogr...AIM: To evaluate central macular thickness(CMT) and mean choroidal thickness(MCT) in eyes with branch retinal vein occlusion(BRVO), before and after ranibizumab treatment using spectral domain-optical coherence tomography(SD-OCT).·METHODS: Forty-two patients with unilateral BRVO and macular edema were included in this study. There were 25 men and 17 women. Using SD-OCT, choroidal thickness was measured at 500 μm intervals up to 1500μm temporal and nasal to the fovea. MCT was calculated based on the average of the 7 locations. All the eyes with BRVO were treated with intravitreal ranibizumab(0.5 mg/0.05 m L). Comparisons between the BRVO and fellow eyes were analyzed using Mann-Whitney U test. Preinjection and post-injection measurements were analyzed using Wilcoxon test and repeated measure analysis.· RESULTS: At baseline, there was a significant difference between the BRVO and fellow eyes in MCT[BRVO eyes 245(165-330) μm, fellow eyes 229(157-327) μm]and CMT [BRVO eyes 463(266-899) μm, fellow eyes 235(148-378) μm(P =0.041, 0.0001, respectively)]. Following treatment, CMT [295(141-558) μm] and MCT [229(157-329) μm] decreased significantly compared to the baseline measurements(P =0.001, 0.006, respectively).Also BCVA(log MAR) improved significantly(P=0.0001) in the BRVO eyes following treatment. After treatment CMT[BRVO eyes 295(141-558) μm, fellow eyes 234(157-351) μm]and MCT [BRVO eyes 229(157-329) μm, fellow eyes 233(162-286) μm] values did not reveal any significant difference in BRVO eyes and fellow eyes(P=0.051, 0.824,respectively).· CONCLUSION: In eyes with BRVO, CMT and MCT values are greater than the fellow eyes, and decrease significantly following ranibizumab injection.展开更多
● AIM: To evaluate the inhibitory effect of subconjunctival bevacizumab as single-and multiple-dose application, and compare their effects on corneal neovascularization in a rat model.● METHODS: Thirty adult Sprague...● AIM: To evaluate the inhibitory effect of subconjunctival bevacizumab as single-and multiple-dose application, and compare their effects on corneal neovascularization in a rat model.● METHODS: Thirty adult Sprague-Dawley rats were used in this experimental study. The central cornea of the rats was cauterized chemically. The rats were randomly enrolled into three groups. All groups received subconjunctival injections. In Group 1(control group, n=10), 0.05 m L 0.9% Na Cl solution was injected on the first day. In Group 2(single-dose group, n=10), 0.05 m L bevacizumab(1.25 mg) was injected on the first day. In Group 3(multiple-dose group, n=10), four doses of 0.05 m L bevacizumab(1.25 mg) were injected on the first, third, fifth and seventh day. Slit-lamp examination of all rats was performed at the third and ninth day. Digital images of the corneas were taken and analyzed using image analysis software to calculate corneal neovascularization area. All rats were sacrificed on the tenth day. In corneal sections, the number of blood vessels, state of inflammation and collagen formation was evaluated histopathologically.● RESULTS: In Group 3, corneal edema grades were significantly lower than Group 1 and Group 2(P=0.02, and P=0.035, respectively). The mean percentage of neovascularized corneal area in Group 3 was significantly lower than Group 2(P=0.005). On histopathological examination, Group 2 and Group 3 showed significantly less number of blood vessels than Group 1(P=0.005, and P=0.001, respectively). Additionally, Group 3 showed significantly less number of blood vessels compared to Group 2(P=0.019). Inflammation and edema grades were significantly lower in Group 3 compared to Group 1(P=0.001).● CONCLUSION: Subconjunctival bevacizumab injection is effective in inhibition of newly formed corneal neovascularization. The multiple-dose bevacizumab treatment seems to be more effective compared to single-dose treatment.展开更多
AIM: To evaluate the clinical characteristics of adenoviral keratoconjunctivitis, the management modalities, as well as the incidence of subepithelial corneal infiltrates(SEI).METHODS: Patients with characteristic cli...AIM: To evaluate the clinical characteristics of adenoviral keratoconjunctivitis, the management modalities, as well as the incidence of subepithelial corneal infiltrates(SEI).METHODS: Patients with characteristic clinical symptoms and signs, who presented to our clinic within the first week of symptoms and received the diagnosis of adenoviral keratoconjunctivitis between January 2013 and April 2016, were included in the study. A total of 211 patients were included in the study. Patients were evaluated for the incidence of clinical signs, late complications, management preferences, and the effect of diluted povidone-iodine(d-PVP-I) 2%. RESULTS: Patients’ mean age was 33.03±14.76 y. We observed an increase in the number of cases according to the years. At presentation and/or early follow-up, the clinical signs were conjunctival hyperemia(100%), conjunctival follicules(79.1%), edema of the eyelids(39.3%), chemosis(16.1%), pseudomembrane formation(16.6%), and corneal epitheliopathy(29.9%). During late follow-up 13.3% patients developed conjunctival subepithelial fibrosis, and 39.8% developed SEI. A significant decrease in the incidence of SEI development was observed in patients who used d-PVP-I 2%(P=0.032;33.3% vs 45.9%, respectively in patients who received d-PVP-I 2% and who did not).CONCLUSION: Adenoviral keratoconjunctivitis has a tremendous effect on patient’s comfort and abilities in short-term. Additionally, almost half of the patients develop visual problems related to SEI. According to our clinical experience, using d-PVP-I 2% in the first days of adenoviral keratoconjunctivitis might be helpful in reducing the risk of SEI as a complication.展开更多
文摘AIM: To evaluate central macular thickness(CMT) and mean choroidal thickness(MCT) in eyes with branch retinal vein occlusion(BRVO), before and after ranibizumab treatment using spectral domain-optical coherence tomography(SD-OCT).·METHODS: Forty-two patients with unilateral BRVO and macular edema were included in this study. There were 25 men and 17 women. Using SD-OCT, choroidal thickness was measured at 500 μm intervals up to 1500μm temporal and nasal to the fovea. MCT was calculated based on the average of the 7 locations. All the eyes with BRVO were treated with intravitreal ranibizumab(0.5 mg/0.05 m L). Comparisons between the BRVO and fellow eyes were analyzed using Mann-Whitney U test. Preinjection and post-injection measurements were analyzed using Wilcoxon test and repeated measure analysis.· RESULTS: At baseline, there was a significant difference between the BRVO and fellow eyes in MCT[BRVO eyes 245(165-330) μm, fellow eyes 229(157-327) μm]and CMT [BRVO eyes 463(266-899) μm, fellow eyes 235(148-378) μm(P =0.041, 0.0001, respectively)]. Following treatment, CMT [295(141-558) μm] and MCT [229(157-329) μm] decreased significantly compared to the baseline measurements(P =0.001, 0.006, respectively).Also BCVA(log MAR) improved significantly(P=0.0001) in the BRVO eyes following treatment. After treatment CMT[BRVO eyes 295(141-558) μm, fellow eyes 234(157-351) μm]and MCT [BRVO eyes 229(157-329) μm, fellow eyes 233(162-286) μm] values did not reveal any significant difference in BRVO eyes and fellow eyes(P=0.051, 0.824,respectively).· CONCLUSION: In eyes with BRVO, CMT and MCT values are greater than the fellow eyes, and decrease significantly following ranibizumab injection.
文摘● AIM: To evaluate the inhibitory effect of subconjunctival bevacizumab as single-and multiple-dose application, and compare their effects on corneal neovascularization in a rat model.● METHODS: Thirty adult Sprague-Dawley rats were used in this experimental study. The central cornea of the rats was cauterized chemically. The rats were randomly enrolled into three groups. All groups received subconjunctival injections. In Group 1(control group, n=10), 0.05 m L 0.9% Na Cl solution was injected on the first day. In Group 2(single-dose group, n=10), 0.05 m L bevacizumab(1.25 mg) was injected on the first day. In Group 3(multiple-dose group, n=10), four doses of 0.05 m L bevacizumab(1.25 mg) were injected on the first, third, fifth and seventh day. Slit-lamp examination of all rats was performed at the third and ninth day. Digital images of the corneas were taken and analyzed using image analysis software to calculate corneal neovascularization area. All rats were sacrificed on the tenth day. In corneal sections, the number of blood vessels, state of inflammation and collagen formation was evaluated histopathologically.● RESULTS: In Group 3, corneal edema grades were significantly lower than Group 1 and Group 2(P=0.02, and P=0.035, respectively). The mean percentage of neovascularized corneal area in Group 3 was significantly lower than Group 2(P=0.005). On histopathological examination, Group 2 and Group 3 showed significantly less number of blood vessels than Group 1(P=0.005, and P=0.001, respectively). Additionally, Group 3 showed significantly less number of blood vessels compared to Group 2(P=0.019). Inflammation and edema grades were significantly lower in Group 3 compared to Group 1(P=0.001).● CONCLUSION: Subconjunctival bevacizumab injection is effective in inhibition of newly formed corneal neovascularization. The multiple-dose bevacizumab treatment seems to be more effective compared to single-dose treatment.
文摘AIM: To evaluate the clinical characteristics of adenoviral keratoconjunctivitis, the management modalities, as well as the incidence of subepithelial corneal infiltrates(SEI).METHODS: Patients with characteristic clinical symptoms and signs, who presented to our clinic within the first week of symptoms and received the diagnosis of adenoviral keratoconjunctivitis between January 2013 and April 2016, were included in the study. A total of 211 patients were included in the study. Patients were evaluated for the incidence of clinical signs, late complications, management preferences, and the effect of diluted povidone-iodine(d-PVP-I) 2%. RESULTS: Patients’ mean age was 33.03±14.76 y. We observed an increase in the number of cases according to the years. At presentation and/or early follow-up, the clinical signs were conjunctival hyperemia(100%), conjunctival follicules(79.1%), edema of the eyelids(39.3%), chemosis(16.1%), pseudomembrane formation(16.6%), and corneal epitheliopathy(29.9%). During late follow-up 13.3% patients developed conjunctival subepithelial fibrosis, and 39.8% developed SEI. A significant decrease in the incidence of SEI development was observed in patients who used d-PVP-I 2%(P=0.032;33.3% vs 45.9%, respectively in patients who received d-PVP-I 2% and who did not).CONCLUSION: Adenoviral keratoconjunctivitis has a tremendous effect on patient’s comfort and abilities in short-term. Additionally, almost half of the patients develop visual problems related to SEI. According to our clinical experience, using d-PVP-I 2% in the first days of adenoviral keratoconjunctivitis might be helpful in reducing the risk of SEI as a complication.
